Gimsilumab
Gimsilumab (MORAb-022) is a human anti-GM-CSF monoclonal antibody. Gimsilumab has the potential for the research of COVID-19 and rheumatoid arthritis (RA) [1][2].
Product Specifications
CAS Number
1648796-29-5
Product Name Alternative
MORAb-022
UNSPSC
12352203
Target
C-Fms; SARS-CoV
Type
Inhibitory Antibodies
Related Pathways
Anti-infection; Protein Tyrosine Kinase/RTK
Applications
COVID-19-anti-virus
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/gimsilumab.html
Purity
98.00
Solubility
10 mM in DMSO
Smiles
[Gimsilumab]
Molecular Weight
(145.765 kDa)
References & Citations
[1]Criner GJ, et al. Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med. 2022 Jun 1;205 (11) :1290-1299. |[2]Crotti C, et al. Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Des Devel Ther. 2017 Jan 13;11:211-223.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY422382 100 µg
HSPC142 (BABAM1) (NM_001033549) Human Over-expression Lysate
Sign In for Pricing
View Details 